BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2014

View Archived Issues

Amarantus and Washington University School of Medicine collaborate in Wolfram syndrome

Read More

Servier and miRagen extend microRNA-targeting drug collaboration

Read More

BioLineRx in-licenses compound for neuropathic pain

Read More

Galectin Therapeutics reports preclinical data for GR-MD-02 from mouse model of NASH

Read More

Questcor Pharmaceuticals to acquire rights to Synacthen and Synacthen Depot

Read More

Discovery and characterization of novel broad-spectrum antibacterial agents

Read More

Phase I data for selective inhibitor of ACAT-1 in adrenocortical carcinoma

Read More

Safety and efficacy data reported for VRS-317, a novel long-acting rhGH

Read More

Testosterone levels increased for over 28 days in healthy men by lasofoxifene

Read More

A modified activin B propeptide to reverse activin-induced muscle wasting

Read More

Karyopharm's selinexor enters phase II trial in acute myeloid leukemia

Read More

Coherus' etanercept biosimilar enters phase III trial in rheumatoid arthritis

Read More

Auspex reports results from SD-809 switching study in Huntington's disease

Read More

Merck & Co. reports discovery of OX2 receptor antagonists

Read More

Chinese company discloses new cancer treatment

Read More

Lumacaftor/ivacaftor achieves endpoints in phase III cystic fibrosis trials

Read More

Sunshine Lake Pharma synthesizes novel HCV NS5A inhibitors

Read More

Novel FFA1 receptor agonists reported in Boehringer Ingelheim patent

Read More

French group details novel Na+/I- cotransporter inhibitors

Read More

Bionomics and Merck & Co. collaborate to develop BNC-375 for cognitive dysfunction

Read More

Catch-up growth seen with weekly injection of Lagova in phase II study

Read More

FDA advisory committee votes against accelerated approval of olaparib for ovarian cancer

Read More

Sobi files for E.U. approval of Xiapex for Peyronie's disease

Read More

Lundbeck completes acquisition of Chelsea Therapeutics

Read More

EMA accepts Ravicti MAA

Read More

FDA accepts Merck & Co.'s NDA for fixed-dose raltegravir and lamivudine

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing